Advances in Peanut Allergy

This program will include a discussion of investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Pathophysiology of Peanut Allergy

Peanut Allergy Prevalence and Natural Course

Peanut Allergy Burden

Allergy vs Tolerance

LEAP Study Design

LEAP Prevalence of Peanut Allergy at 60 Months of Age

LEAP-On Prevalence of Peanut Allergy 12 Months After Avoidance

LEAP and LEAP-On Key Findings

NIAID Recommendations For Risk Reduction of Peanut Allergy

Risk Reduction for Peanut Protein Exposure

Thresholds for Peanut Allergy

Factors That Can Influence Threshold Dose

Significance of Threshold Dose

Exposure Dose Calculation

Peanut Immunotherapies in Development

QRA Modeling Clinical Relevance of Higher Threshold

QRA Modeling Take Home Messages

Peanut Allergen Immunotherapy

Peanut Allergy Current Management Strategies

Allergen Immunotherapy Premise

Desensitization vs Tolerance vs Sustained Unresponsiveness in Food Allergy Literature

Immunotherapies in Development

PALISADE Phase 3 Trial ITT Efficacy Results

PALISADE Safety Results

PEPITES Phase 3 Trial Preliminary Efficacy Results

PEPITES Preliminary Safety Results

OIT Limitations and Advantages

EPIT Limitations and Advantages

SLIT Limitations and Advantages

Summary

Abbreviations